

Vaccine Candidates with Published Results from Phase 1-3 Clinical Trials

Last updated: December 10, 2020

Compound Name	Sponsor	Type of Vaccine	Funding Source	Current Trial Phase	Publications
Ad5-nCoV	CanSino Biologics	Adenovirus Type 5 Vector	CanSino Biologics	Phase 3	Phase 2 Zhu, August 2020 Phase 1 Zhu, June 2020
AZD1222 (formerly ChAdOx1 nCoV-19)	Oxford University, AstraZeneca, IQVIA, Serum Institute of India	Weakened adenovirus	Operation Warp Speed, UK Ministry of Health, Oxford University, BARDA	Phase 2/3	Phase 3 Voysey, December 2020 Phase 2/3 Ramasamy, November 2020 Phase 1/2a Folegatti, August 2020
BNT162	Pfizer, BioNTech	Lipid nanoparticle-formulated, nucleoside-modified mRNA	Pfizer, BioNTech	Phase 3	Phase 3 Polack, December 2020 Phase 1/2 Walsh, October 2020 ; Mulligan, August 2020
Coronavac (formerly PiCoVacc)	Sinovac	Inactivated SARS-CoV-2 with aluminum hydroxide adjuvant	Sinovac	Phase 3	Phase 1/2 Zhang, August 2020
Inactivated COVID-19	Wuhan Institute of Biological Products, Sinopharm	Inactivated SARS-CoV-2	China Ministry of Science and Technology	Phase 3	Phase 1/2 Xia, August 2020
mRNA-1273	Moderna	Lipid nanoparticle - encapsulated mRNA	Operation Warp Speed, NIAID, BARDA	Phase 3	Phase 3 Primary Efficacy Analysis Press Statement Phase 1/2 Anderson, September

					2020; Jackson, July 2020
NVX-CoV2373	Novavaxx	Recombinant SARS-CoV-2 glycoprotein nanoparticle adjuvanted with Matrix M	Novavax, CEPI, Department of Defense	Phase 2b	Phase 1/2 Keech, September 2020
Gam-COVID-Vac Lyo/ Gam-COVID-Vac	Gamaleya Research Institute of Epidemiology and Microbiology, Russian Ministry of Health	Recombinant adenovirus type 26 (rAd26) and recombinant adenovirus type 5 (rAd5) vector	Russian Ministry of Health	Phase 2	Phase 1/2 Logunov, September 2020
BBIBP-CorV	Sinopharm	Inactivated SARS-CoV-2	China's National Program on Key Research, National Mega Projects for Major Infectious Diseases, National Mega Projects for New Drug Creation, Beijing Science and Technology Plan	Phase 1/2	Phase 1/2 Xia, October 2020